193 related articles for article (PubMed ID: 22027586)
1. Serum interleukin 1 receptor antagonist as an independent marker of non-alcoholic steatohepatitis in humans.
Pihlajamäki J; Kuulasmaa T; Kaminska D; Simonen M; Kärjä V; Grönlund S; Käkelä P; Pääkkönen M; Kainulainen S; Punnonen K; Kuusisto J; Gylling H; Laakso M
J Hepatol; 2012 Mar; 56(3):663-70. PubMed ID: 22027586
[TBL] [Abstract][Full Text] [Related]
2. [Correlation between interleukin-1 and the obesity of polycystic ovary syndrome].
Yang Y; Qiao J; Li MZ
Zhonghua Fu Chan Ke Za Zhi; 2012 Jan; 47(1):9-13. PubMed ID: 22455686
[TBL] [Abstract][Full Text] [Related]
3. [Relationship between morphological diagnosis of NASH (non-alcoholic steatohepatitis) and liver function tests in a group of patients with morbid obesity].
Chavarría-Arciniega S; López-Alvarenga JC; Uribe-Uribe NO; Herrera-Hernández M; González-Barranco J
Rev Invest Clin; 2005; 57(4):505-12. PubMed ID: 16315634
[TBL] [Abstract][Full Text] [Related]
4. Relationship of insulin resistance and adipocytokines on serum alanine aminotransferase in presurgical morbid obese patients.
de Luis DA; Aller R; Izaola O; Gonzalez Sagrado M; Conde R; de la Fuente B; Perez Castrillon JL
Eur Rev Med Pharmacol Sci; 2009; 13(6):413-8. PubMed ID: 20085121
[TBL] [Abstract][Full Text] [Related]
5. Serum intercellular adhesion molecule-1 in patients with nonalcoholic steatohepatitis: comparison with alcoholic hepatitis.
Ito S; Yukawa T; Uetake S; Yamauchi M
Alcohol Clin Exp Res; 2007 Jan; 31(1 Suppl):S83-7. PubMed ID: 17331172
[TBL] [Abstract][Full Text] [Related]
6. Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease.
Liew PL; Lee WJ; Lee YC; Wang HH; Wang W; Lin YC
Obes Surg; 2006 Dec; 16(12):1584-93. PubMed ID: 17217634
[TBL] [Abstract][Full Text] [Related]
7. [Clinical and histological features of non-alcoholic fatty liver disease].
Shi JP; Xun YH; Hu CB; Zhang L; Liu H; Lou GQ; Fan JG
Zhonghua Gan Zang Bing Za Zhi; 2009 Nov; 17(11):812-6. PubMed ID: 19958638
[TBL] [Abstract][Full Text] [Related]
8. Noninvasive clinical model for the diagnosis of nonalcoholic steatohepatitis in overweight and morbidly obese patients undergoing bariatric surgery.
Pirvulescu I; Gheorghe L; Csiki I; Becheanu G; Dumbravă M; Fica S; Martin S; Sarbu A; Gheorghe C; Diculescu M; Copăescu C
Chirurgia (Bucur); 2012; 107(6):772-9. PubMed ID: 23294957
[TBL] [Abstract][Full Text] [Related]
9. Plasma IL-1 receptor antagonist levels correlate with the development of non-alcoholic steatohepatitis.
Hendrikx T; Walenbergh SM; Jeurissen ML; Houben T; van Gorp PJ; Lindsey PJ; Koek GH; Kalhan S; Pihlajamaki J; Hofker MH; Shiri-Sverdlov R
Biomark Med; 2015; 9(12):1301-9. PubMed ID: 26612588
[TBL] [Abstract][Full Text] [Related]
10. Expression of adiponectin and its receptors in livers of morbidly obese patients with non-alcoholic fatty liver disease.
Ma H; Gomez V; Lu L; Yang X; Wu X; Xiao SY
J Gastroenterol Hepatol; 2009 Feb; 24(2):233-7. PubMed ID: 18713296
[TBL] [Abstract][Full Text] [Related]
11. Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels.
Wong VW; Wong GL; Tsang SW; Hui AY; Chan AW; Choi PC; Chim AM; Chu S; Chan FK; Sung JJ; Chan HL
Aliment Pharmacol Ther; 2009 Feb; 29(4):387-96. PubMed ID: 19035982
[TBL] [Abstract][Full Text] [Related]
12. A gene variant of PNPLA3, but not of APOC3, is associated with histological parameters of NAFLD in an obese population.
Verrijken A; Beckers S; Francque S; Hilden H; Caron S; Zegers D; Ruppert M; Hubens G; Van Marck E; Michielsen P; Staels B; Taskinen MR; Van Hul W; Van Gaal L
Obesity (Silver Spring); 2013 Oct; 21(10):2138-45. PubMed ID: 23512881
[TBL] [Abstract][Full Text] [Related]
13. Serum fragmented cytokeratin 18 levels reflect the histologic activity score of nonalcoholic fatty liver disease more accurately than serum alanine aminotransferase levels.
Tsutsui M; Tanaka N; Kawakubo M; Sheena Y; Horiuchi A; Komatsu M; Nagaya T; Joshita S; Umemura T; Ichijo T; Matsumoto A; Yoshizawa K; Aoyama T; Tanaka E; Sano K
J Clin Gastroenterol; 2010 Jul; 44(6):440-7. PubMed ID: 20104187
[TBL] [Abstract][Full Text] [Related]
14. Non-alcoholic steatohepatitis (NASH) in patients with polycystic ovarian syndrome (PCOS).
Hossain N; Stepanova M; Afendy A; Nader F; Younossi Y; Rafiq N; Goodman Z; Younossi ZM
Scand J Gastroenterol; 2011 Apr; 46(4):479-84. PubMed ID: 21114431
[TBL] [Abstract][Full Text] [Related]
15. Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement.
Dixon JB; Bhathal PS; O'Brien PE
Obes Surg; 2006 Oct; 16(10):1278-86. PubMed ID: 17059735
[TBL] [Abstract][Full Text] [Related]
16. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone.
Neuschwander-Tetri BA; Brunt EM; Wehmeier KR; Oliver D; Bacon BR
Hepatology; 2003 Oct; 38(4):1008-17. PubMed ID: 14512888
[TBL] [Abstract][Full Text] [Related]
17. Visceral adipose tissue and inflammation correlate with elevated liver tests in a cohort of overweight and obese patients.
Verrijken A; Francque S; Mertens I; Talloen M; Peiffer F; Van Gaal L
Int J Obes (Lond); 2010 May; 34(5):899-907. PubMed ID: 20142825
[TBL] [Abstract][Full Text] [Related]
18. Desmosterol in human nonalcoholic steatohepatitis.
Simonen M; Männistö V; Leppänen J; Kaminska D; Kärjä V; Venesmaa S; Käkelä P; Kuusisto J; Gylling H; Laakso M; Pihlajamäki J
Hepatology; 2013 Sep; 58(3):976-82. PubMed ID: 23447451
[TBL] [Abstract][Full Text] [Related]
19. Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease.
Lemoine M; Ratziu V; Kim M; Maachi M; Wendum D; Paye F; Bastard JP; Poupon R; Housset C; Capeau J; Serfaty L
Liver Int; 2009 Oct; 29(9):1431-8. PubMed ID: 19422483
[TBL] [Abstract][Full Text] [Related]
20. Adipohormones as prognostric markers in patients with nonalcoholic steatohepatitis (NASH).
Krawczyk K; Szczesniak P; Kumor A; Jasinska A; Omulecka A; Pietruczuk M; Orszulak-Michalak D; Sporny S; Malecka-Panas E
J Physiol Pharmacol; 2009 Oct; 60 Suppl 3():71-5. PubMed ID: 19996485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
